Xenon Pharmaceuticals Inc. (XENE) Stock Forecast
XENE analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.74 / 5 from 19 analysts
- Price target
- $72.42 average of analyst targets
- Upside to target
- +116.3% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $-1.17
- 52-week range
- $33.49 – $70.96
XENE analyst ratings
19 analystsNumber of analysts at each rating.
XENE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
XENE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.15 | −$1.29 | −$0.94 | −$1.15 | −0.0% | 13 |
| Current fiscal year (2026) | −$4.63 | −$4.93 | −$4.06 | −$4.36 | −6.2% | 14 |
| Next fiscal year (2027) | −$4.72 | −$5.50 | −$1.90 | −$4.63 | −2.1% | 14 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
XENE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 15 |
| Current fiscal year (2026) | $1.3M | $0 | $7.6M | −83.2% | 16 |
| Next fiscal year (2027) | $27.0M | $0 | $175.0M | +2,045.7% | 15 |
XENE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
XENE revenue: reported and forecast
XENE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.19 | −$1.16 | −$1.15 | −$1.15 | −$1.15 | −3.7% | 1 up · 0 down |
| Current fiscal year (2026) | −$4.81 | −$4.61 | −$4.63 | −$4.63 | −$4.63 | −3.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$5.01 | −$4.86 | −$4.80 | −$4.71 | −$4.72 | −5.7% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
XENE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; XENE beat in 7 of 12.
What analysts expect from XENE
19 analysts cover Xenon Pharmaceuticals; their consensus rating is strong buy (4.74 on a 1–5 scale, where 5 is a strong buy). The average price target is $72.42, 116.3% above the latest close of $33.49. Analysts expect earnings of −$4.63 per share for 2026, −6.2% from a year earlier. For 2027 the average estimate is −$4.72 per share on revenue of $27.0 million. Xenon Pharmaceuticals beat the EPS estimate in 7 of the last 12 quarters.
Related: XENE income statement, XENE key metrics, XENE chart. See the XENE stock overview for the latest quote and news.
XENE forecast FAQ
What is Xenon Pharmaceuticals's price target?
The average analyst price target for Xenon Pharmaceuticals is $72.42, 116.3% above the latest close of $33.49.
Is Xenon Pharmaceuticals a buy, hold or sell?
Of 19 analysts covering Xenon Pharmaceuticals, 15 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Xenon Pharmaceuticals's EPS forecast?
Analysts forecast −$4.63 per share for 2026 (range −$4.93 to −$4.06); for 2027 the estimate is −$4.72.
What is Xenon Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $1.3 million, growth of −83.2%; for 2027 it is $27.0 million.
When does Xenon Pharmaceuticals report earnings?
Xenon Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes; the EPS estimate is $-1.17.
Does Xenon Pharmaceuticals usually beat earnings estimates?
Xenon Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 12 quarters.